Radiation-induced xerostomia

treatment of head and neck squamous carcinoma. Semin
Radiat Oncol 2004;14:153–166.
3. Wong RK, Jones GW, Sagar SM, Babjak AF, Whelan T.
A Phase I–II study in the use of acupuncture-like transcutaneous
nerve stimulation in the treatment of radiation-induced
xerostomia in head-and-neck cancer patients
treated with radical radiotherapy. Int J Radiat
Oncol Biol Phys 2003;57:472–480.
4. Wescott WB, Mira JG, Starcke EN, Shannon IL,
Thornby JI. Alterations in whole saliva flow rate induced
by fractionated radiotherapy. AJR Am J Roentgenol 1978;
130:145–149.
5. Liu RP, Fleming TJ, Toth BB, Keene HJ. Salivary flow
rates in patients with head and neck cancer 0.5 to 25
years after radiotherapy. Oral Surg Oral Med Oral Pathol
1990;70:724–729.
6. Taylor SE. Efficacy and economic evaluation of pilocarpine
in treating radiation-induced xerostomia. Expert
Opin Pharmacother 2003;4:1489–1497.
7. Frydrych AM, Davies GR, Slack-Smith LM, Heywood J.
An investigation into the use of pilocarpine as a sialagogue
in patients with radiation induced xerostomia.
Aust Dent J 2002;47:249–253.
8. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA,
Ship JA. Xerostomia and its predictors following parotidsparing
irradiation of head-and-neck cancer. Int J Radiat
Oncol Biol Phys 2001;50:695–704.
9. Bruce SD. Radiation-induced xerostomia: how dry is
your patient Clin J Oncol Nurs 2004;8:61–67.
10. Peterson DE. Oral problems in supportive care: no longer
an orphan topic Support Care Cancer 2000;8:347–348.
11. Atkinson JC, Baum BJ. Salivary enhancement: current
status and future therapies. J Dent Educ 2001;65:1096–
1101.
12. Jha N, Seikaly H, McGaw T, Coulter L. Submandibular
salivary gland transfer prevents radiation-induced xerostomia.
Int J Radiat Oncol Biol Phys 2000;46:7–11.
13. Cancer Therapy Evaluation Program, Common Terminology
Criteria for Adverse Events, Version 3.0, DCTD, NCI,
NIH, DHHS. March 31, 2003. Available at: http://ctep.
cancer.gov/reporting/ctc.html. Accessed January 27, 2006.
14. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore
P. Quality of life and oral function in patients
treated with radiation therapy for head and neck cancer.
Head Neck 2001;23:389–398.
15. Papas AS, Joshi A, MacDonald SL, et al. Caries prevalence
in xerostomic individuals. J Can Dent Assoc 1993;
59:171–174;177–179.
16. Oral Cancer Background Papers. National Strategic
Planning Conference for the Prevention and Control of
Oral and Pharyngeal Cancer, August 7–9, 1996, Chicago,
Illinois. Available at: http://www.cdc.gov/oralhealth/pdfs/
oc-bgpapers.pdf. Accessed May 16, 2006.
17. Nagler RM, Baum BJ. Prophylactic treatment reduces
the severity of xerostomia following radiation therapy
for oral cavity cancer. Arch Otolaryngol Head Neck Surg
2003;129:247–250.
18. Chao KS, Majhail N, Huang C-J, et al. Intensity-modulated
radiation therapy reduces late salivary toxicity without
compromising tumor control in patients with oropharyngeal
carcinoma: a comparison with conventional techniques.
Radiother Oncol 2001;61:275–280.
19. Lee N, Xia P, Quivey JM, et al. Intensity-modulated
radiotherapy in the treatment of nasopharyngeal carcinoma:
an update of the UCSF experience. Int J Radiat
Oncol Biol Phys 2002;53:12–22.
20. Bohuslavizki KH, Klutmann S, Brenner W, Mester J,
Henze E, Clausen M. Salivary gland protection by amifostine
in high-dose radioiodine treatment: results of a
double-blind placebo-controlled study. J Clin Oncol 1998;
16:3542–3549.
21. Brizel DM, Wasserman T. The influence of intravenous
amifostine on xerostomia and survival during radiotherapy
for head and neck cancer: two-year follow-up of prospective
randomized trial. J Clin Oncol 2004;22(14 suppl):
5536.
22. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002
update of recommendations for the use of chemotherapy
and radiotherapy protectants: clinical practice guidelines
of the American Society of Clinical Oncology. J Clin
Oncol 2002;20:2895–2903.
23. Hensley ML, Schuchter LM, Lindley C, et al. American
Society of Clinical Oncology clinical practice guidelines
for the use of chemotherapy and radiotherapy protectants.
J Clin Oncol 1999;17:3333–3355.
24. Koukourakis MI, Simopoulos C, Minopoulos G, et al.
Amifostine before chemotherapy: improved tolerance
profile of the subcutaneous over the intravenous route.
Clin Cancer Res 2003;9:3288–3293.
25. Johnstone PA, Niemtzow RC, Riffenburgh RH. Acupuncture
for xerostomia: clinical update. Cancer 2002;94:
1151–1156.
26. Seikaly H, Jha N, McGaw T, Coulter L, Liu R, Oldring D.
Submandibular gland transfer: a new method of preventing
radiation-induced xerostomia. Laryngoscope 2001; 111:
347–352.
27. Chambers M, Garden A, Klies M, Martin J. Radiationinduced
xerostomia in patients with head and neck cancer:
pathogenesis, impact on quality of life, and management.
Head Neck 2004;26:796–807.
28. Johnson JT, Ferretti GA, Nethery WJ, et al. Oral pilocarpine
for post-irradiation xerostomia in patients with
head and neck cancer. N Engl J Med 1993;329:390–395.
29. Haddad P, Karimi M. A randomized, double-blind, placebo-controlled
trial of concomitant pilocarpine with
head and neck irradiation for prevention of radiationinduced
xerostomia. Radiother Oncol 2002;64:29–32.
30. Fisher J, Scott C, Scarantino CW, et al. Phase III quality-of-life
study results: impact on patients’ quality of life
to reducing xerostomia after radiotherapy for head-andneck
cancer—RTOG 97–09. Int J Radiat Oncol Biol Phys
2003;56:832–836.
31. Salagen tablets (pilocarpine hydrochloride) [package
insert]. Bloomington, Minn: MGI Pharma, Inc; 2003.
32. Iwabuchi Y, Masuhara T. Sialagogic activities of SNI-
2011 compared with those of pilocarpine and McN-A-343
in rat salivary glands: identification of a potential therapeutic
agent for treatment of Sjögren’s syndrome. Gen
Pharmacol 1994;25:123–129.
33. Evoxac capsules (cevimeline hydrochloride) [package
insert]. Montvale, NJ: Daiichi Pharmaceutical Corporation;
2005.
34. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin
P. A double-blind, randomized, placebo-controlled
study of cevimeline in Sjögren’s syndrome patients with
xerostomia and keratoconjunctivitis sicca. Arthritis Rheum
2002;46:748–754.
35. Fife RS, Chase WF, Dore RK, et al. Cevimeline for the
treatment of xerostomia in patients with Sjögren syndrome:
a randomized trial. Arch Intern Med 2002;162:
1293–1300.
36. Chambers MS, Posner MR, Jones CU, Weber RS, Vitti R.
Two phase III clinical studies of cevimeline for postirradiation
xerostomia in patients with head and neck cancer.
Presented at the 2005 Annual Meeting of the American
Society of Clinical Oncology. Abstract no. 5503. Available
at: http://www.asco.org/ac/1,1003, 12-002643-00_18-0034-
00_19-0031963,00.asp. Accessed August 15, 2005.
Radiation-Induced Xerostomia HEAD & NECK—DOI 10.1002/hed January 2007 63